- Clinical Trials
- April 2025
- 450 Pages
Global
From €4367EUR$5,000USD£3,793GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1310EUR$1,500USD£1,138GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1310EUR$1,500USD£1,138GBP
- Report
- October 2024
- 200 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- January 2025
- 182 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- May 2025
- 183 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- April 2025
- 184 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- February 2025
- 184 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- February 2025
- 221 Pages
Global
From €2183EUR$2,500USD£1,897GBP
- Report
- June 2025
- 400 Pages
Global
From €4322EUR$4,949USD£3,755GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Report
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Report
- June 2025
- 150 Pages
Global
From €2357EUR$2,699USD£2,048GBP
- Report
- January 2025
- 140 Pages
Global
From €2760EUR$3,160USD£2,397GBP
€3450EUR$3,950USD£2,997GBP
- Report
- May 2025
- 90 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- May 2025
- 81 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- August 2025
- 98 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- April 2025
- 90 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- June 2025
- 131 Pages
Global
From €13095EUR$14,995USD£11,376GBP

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications.
The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more